Delivery Order 36F79719D0224-36C24524N0929
Award Date
9/20/24
Potential Completion Date
9/24/24
Potential Value
$56K
Federal Agency
Veterans Integrated Service Network 5
Awardee
Horizon Therapeutics Usa, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
La Vergne, TN 37086, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of KRYSTEXXA 8MG, a specialty pharmaceutical product, to the Department of Veterans Affairs (VA) Veterans Health Administration (VHA). The contract was awarded to Horizon Therapeutics USA, Inc., a global biotechnology company that provides orphan drugs and specialty pharmaceuticals. The contract is a Delivery Order placed against Horizon's existing Multiple Award Schedule contract for Pharmaceuticals and Drugs with the General Services...
The U.S. Department of Veterans Affairs (VA) awarded a $76,896.72 firm fixed-price delivery order to Horizon Therapeutics USA, Inc. for the specialty pharmaceutical KRYSTEXXA 8MG. The award is part of Horizon's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB) and is placed by the VA's Veterans Integrated Service Network (VISN) 5. This delivery order supports the VA's mission to provide comprehensive healthcare services to the veteran population, as KRYSTEXXA is...
This contract award is for the delivery of KRYSTEXXA 8MG, a specialty pharmaceutical product, to the United States Department of Veterans Affairs (VA). The contract, valued at $37,268.88, is a firm fixed-price delivery order placed by the VA's Veterans Integrated Service Network 5 (VISN 5) against the prime contractor Horizon Therapeutics USA, Inc.'s Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). Horizon Therapeutics USA, Inc. is a global biotechnology...
The Department of Veterans Affairs Veterans Health Administration (VHA) awarded a delivery order to Horizon Therapeutics USA Inc. for KRYSTEXXA 8MG, a specialty pharmaceutical product. The order, valued at $55,903.32, was placed against Horizon Therapeutics' Multiple Award Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB) and did not have a set-aside designation. Horizon Therapeutics is a global biotechnology company that provides orphan drugs and specialty pharmaceuticals to support...
The Department of Veterans Affairs Veterans Health Administration awarded a $131,372.30 firm fixed price delivery order to Horizon Therapeutics USA Inc., a foreign-owned for-profit organization, for the provision of KRYSTEXXA medication. This order was placed against Horizon Therapeutics' Multiple Award Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The contract has no set-aside designation. Horizon Therapeutics has a $18 million Blanket Purchase Agreement against the...
This federal contract award is for the delivery of KRYSTEXXA 8MG, a specialty pharmaceutical product, to the U.S. Department of Veterans Affairs (VA). The contract was awarded to Horizon Therapeutics USA, Inc., a global biotechnology company that specializes in rare, autoimmune, and inflammatory disease treatments. The $74,667.32 firm fixed-price delivery order was placed against Horizon's existing Pharmaceuticals and Drugs (FSS-61-IB) Multiple Award Schedule contract with the General Services...
The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a firm fixed price delivery order for KRYSTEXXA 8MG to the prime contractor, Horizon Therapeutics USA, Inc. This order, valued at $74,537.76, was placed against Horizon's existing Multiple Award Schedule (MAS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The delivery order has an April 17, 2024 completion date and will provide the specialized orphan drug to VHA hospitals and clinics across the country...
This is a $93,172.20 firm fixed-price delivery order awarded by the Department of Veterans Affairs (VA) to Horizon Therapeutics USA, Inc. for the drug KRYSTEXXA 8MG. The order was placed against Horizon's $25 million Multiple Award Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB) with the VA, which has an expiration date of August 2025. Horizon also holds an $18 million Blanket Purchase Agreement (BPA) against the same Pharmaceuticals and Drugs Schedule, covering the procurement of...
This is a $65,686.15 firm fixed-price delivery order awarded by the U.S. Department of Veterans Affairs (VA) to Horizon Therapeutics USA Inc. under the company's $25 million Multiple Award Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The order is for KRYSTEXXA 8MG/ML, a specialty pharmaceutical used to treat chronic gout. Horizon Therapeutics is a global biotechnology firm that provides critical medications to support healthcare services for veterans through the VA's Veterans...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 awarded Horizon Therapeutics USA Inc. a firm fixed price delivery order valued at fifty-three thousand nine hundred thirteen dollars and eighty-seven cents ($53,913.87) to provide KRYSTEXXA 8MG. The order was placed against Horizon's Pharmaceuticals and Drugs schedule contract with the General Services Administration. Performance will occur in La Vergne, Tennessee over a period of two days...